| Full text | |
| Author(s): |
Fernando Morgadinho Santos Coelho
;
Márcia Pradella-Hallinan
[2]
;
Mario Pedrazzoli
[3]
;
Carlos Augusto Senne Soares
[4]
;
Gustavo Bruniera Peres Fernandes
[5]
;
André Leite Gonçalves
[6]
;
Sergio Tufik
[7]
;
Lia Rita Azeredo Bittencourt
[8]
Total Authors: 8
|
| Document type: | Journal article |
| Source: | Arquivos de Neuro-Psiquiatria; v. 68, n. 5, p. 712-715, 2010-10-00. |
| Abstract | |
This study was thought to characterized clinical and laboratory findings of a narcoleptic patients in an out patients unit at São Paulo, Brazil. METHOD: 28 patients underwent polysomnographic recordings (PSG) and Multiple Sleep Latency Test (MSLT) were analyzed according to standard criteria. The analysis of HLADQB1*0602 allele was performed by PCR. The Hypocretin-1 in cerebral spinal fluid (CSF) was measured using radioimmunoassay. Patients were divided in two groups according Hypocretin-1 level: Normal (N) - Hypocretin-1 higher than 110pg/ml and Lower (L) Hypocretin-1 lower than 110 pg/ml. RESULTS: Only 4 patients of the N group had cataplexy when compared with 14 members of the L group (p=0.0002). DISCUSSION: This results were comparable with other authors, confirming the utility of using specific biomarkers (HLA-DQB1*0602 allele and Hypocretin-1 CSF level) in narcolepsy with cataplexy. However, the HLADQB1*0602 allele and Hypocretin-1 level are insufficient to diagnose of narcolepsy without cataplexy. (AU) | |
| FAPESP's process: | 98/14303-3 - Center for Sleep Studies |
| Grantee: | Sergio Tufik |
| Support Opportunities: | Research Grants - Research, Innovation and Dissemination Centers - RIDC |